Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2014 - 2019)
Zevra Therapeutics' (ZVRA) quarterly Long-Term Deferred Tax came in at $67.7 million in Q4 2019, up 32.1% YoY from $51.3 million in Q4 2018, and up 32.1% on a QoQ basis from $51.3 million in Q4 2018.
Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2014 - 2019) Analysis & Trends
Zevra Therapeutics (ZVRA) has 6 years of Long-Term Deferred Tax data on file, last reported at $67.7 million in Q4 2019.
- Quarterly Long-Term Deferred Tax rose 32.1% year-over-year to $67.7 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $67.7 million (up 32.1% YoY) and the FY2019 annual result came in at $67.7 million, up 32.1% from the prior year.
- Long-Term Deferred Tax advanced to $67.7 million in Q4 2019, from $51.3 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $67.7 million in Q4 2019 to a low of $29.1 million in Q4 2015.
- A 5-year average of $46.0 million and a median of $45.0 million in 2016 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2015 — Long-Term Deferred Tax jumped 77.57% — and 2017, when it slipped 17.69%.
- Tracing ZVRA's Long-Term Deferred Tax over 5 years: stood at $29.1 million in 2015, then soared by 54.57% to $45.0 million in 2016, then decreased by 17.69% to $37.0 million in 2017, then surged by 38.46% to $51.3 million in 2018, then soared by 32.1% to $67.7 million in 2019.
- The last three Long-Term Deferred Tax figures came in at $67.7 million (Q4 2019), $51.3 million (Q4 2018), and $37.0 million (Q4 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 67.73 Mn |
| Dec 31, 2018 | 51.27 Mn |
| Dec 31, 2017 | 37.03 Mn |
| Dec 31, 2016 | 44.98 Mn |
| Dec 31, 2015 | 29.10 Mn |
| Dec 31, 2014 | 16.39 Mn |